Uj lehetóségek a systolés szívelégtelenség gyógyszeres kezelésére.

Péter Andréka, Zoltán Nádházi, László Vándor, Eszter Takács, Gergely Szánthó, László Kónya, Zsolt Tulassay

Research output: Review article


Heart failure is characterized by sodium and fluid retention, sympathetic overactivation, parasympathetic withdrawal, vasoconstrictor activation and cytokine elevation. New therapies for heart failure attempt to control neurohormonal activation and limit progressive left ventricular dysfunction. Nesiritide (human B-type natriuretic peptide) is a recently approved new vasodilator that has been given to almost 1000 patients in numerous clinical investigations, it belongs to a new class of heart failure drugs known as natriuretic peptides. Nesiritide decreases pulmonary capillary wedge pressure, systemic vascular resistance, mean right atrial pressure and pulmonary artery pressure, while improving cardiac index, stroke volume and heart failure symptoms. Many endothelin receptor antagonists are in various stages of development. Early clinical studies have demonstrated beneficial cardiovascular hemodynamic effects. Other new drugs for heart failure also include calcium sensitizers, neutral endopeptidase and vasopeptidase inhibitors, aldosteron receptor antagonists, vasopressin antagonists and cytokine inhibitors. All are being actively investigated and many show significant promise as beneficial therapies in the treatment of heart failure.

Translated title of the contributionNew medical therapies for the treatment of systolic heart failure
Original languageHungarian
Pages (from-to)2053-2062
Number of pages10
JournalOrvosi hetilap
Issue number42
Publication statusPublished - okt. 19 2003

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Uj lehetóségek a systolés szívelégtelenség gyógyszeres kezelésére.'. Together they form a unique fingerprint.

  • Cite this

    Andréka, P., Nádházi, Z., Vándor, L., Takács, E., Szánthó, G., Kónya, L., & Tulassay, Z. (2003). Uj lehetóségek a systolés szívelégtelenség gyógyszeres kezelésére. Orvosi hetilap, 144(42), 2053-2062.